Cargando…

Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab

BACKGROUND: Bevacizumab is used in addition to standard, platinum-based chemotherapy to treat advanced-stage ovarian cancer patients. Thrombosis is a well-documented adverse effect of bevacizumab. OBJECTIVE: The aim of this study was to identify predictive parameters for thromboembolic events in ova...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuk, Anna, Magnowska, Magdalena, Suchy, Wiktor, Swierczynska, Joanna, Zaborowski, Mikolaj Piotr, Gaca, Michal, Nowak-Markwitz, Ewa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524869/ https://www.ncbi.nlm.nih.gov/pubmed/28580507 http://dx.doi.org/10.1007/s11523-017-0496-3

Ejemplares similares

Paraneoplastic neurological syndromes associated with ovarian tumors
por: Zaborowski, Mikolaj Piotr, et al.
Publicado: (2014)

Choriocarcinoma complicated with intra-abdominal and intrapleural hemorrhage in pregnancy – case report
por: Jaz, Kamila, et al.
Publicado: (2023)

Successful pregnancy after conservative management of early stage endometrial carcinoma in a young nulliparous woman
por: Magnowska, Magdalena, et al.
Publicado: (2015)

Vulvar melanoma with urethral invasion and bladder metastases – a case report and review of the literature
por: Lemańska, Agnieszka, et al.
Publicado: (2015)

Cancer Stem Cell Markers—Clinical Relevance and Prognostic Value in High-Grade Serous Ovarian Cancer (HGSOC) Based on The Cancer Genome Atlas Analysis
por: Iżycka, Natalia, et al.
Publicado: (2023)

Serum Proteomic Profiles of Patients with High and Low Risk of Endometrial Cancer Recurrence
por: Pietkiewicz, Dagmara, et al.
Publicado: (2023)

Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy
por: Zaborowski, Mikołaj Piotr, et al.
Publicado: (2020)

Immunotherapy in Ovarian Cancer
por: Siminiak, Natalia, et al.
Publicado: (2022)

Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery
por: Swiatly, Agata, et al.
Publicado: (2018)

Assessment of gynecological and lifestyle-related risk factors of ovarian cancer
por: Abdulaziz, Gazala, et al.
Publicado: (2021)

MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer
por: Swiatly, Agata, et al.
Publicado: (2017)

MALDI-MSI—A Step Forward in Overcoming the Diagnostic Challenges in Ovarian Tumors
por: Pietkiewicz, Dagmara, et al.
Publicado: (2020)

Human Chorionic Gonadotropin Beta Subunit Genes CGB1 and CGB2 are Transcriptionally Active in Ovarian Cancer
por: Kubiczak, Marta, et al.
Publicado: (2013)

Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay
por: Horala, Agnieszka, et al.
Publicado: (2017)

Regulation of human chorionic gonadotropin beta subunit expression in ovarian cancer
por: Śliwa, Aleksandra, et al.
Publicado: (2019)

Expression of the MT1 Melatonin Receptor in Ovarian Cancer Cells
por: Jablonska, Karolina, et al.
Publicado: (2014)

Cell-Mediated Immune Responses in Paraneoplastic Neurological Syndromes
por: Zaborowski, Mikolaj Piotr, et al.
Publicado: (2013)

Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors
por: Gasiorowska, Emilia, et al.
Publicado: (2019)

Usefulness of Amino Acid Profiling in Ovarian Cancer Screening with Special Emphasis on Their Role in Cancerogenesis
por: Plewa, Szymon, et al.
Publicado: (2017)

Estrogen Receptor Alpha Expression in Ovarian Cancer Predicts Longer Overall Survival
por: Halon, Agnieszka, et al.
Publicado: (2011)

The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression—ALDH1A1, CD133, CD44—For Survival and Long-Term Follow-Up of Ovarian Cancer Patients
por: Izycka, Natalia, et al.
Publicado: (2023)

Serum Free Amino Acid Profiling in Differential Diagnosis of Ovarian Tumors—A Comparative Study with Review of the Literature
por: Horala, Agnieszka, et al.
Publicado: (2021)

TLR4 signaling induced by lipopolysacharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer
por: Szajnik, Marta, et al.
Publicado: (2009)

Bevacizumab in the treatment of ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2011)

A Combined Metabolomic and Proteomic Analysis of Gestational Diabetes Mellitus
por: Hajduk, Joanna, et al.
Publicado: (2015)

Is the shear wave sonographic elastography correlated with pain after breast augmentation with silicone implants an indication of inflammatory activity? A preliminary report
por: Rzymski, Paweł, et al.
Publicado: (2011)

Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer
por: Sasaki, Akinori, et al.
Publicado: (2020)

Necrotizing Fasciitis in a Patient with Metastatic Clear Cell Ovarian Carcinoma Treated with Bevacizumab
por: Haider, Asim, et al.
Publicado: (2022)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
por: Dziadkowiec, Karolina N., et al.
Publicado: (2017)

Cervicomedullary hemangioblastoma treated with bevacizumab
por: Mak, Gloria, et al.
Publicado: (2020)

Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab
por: Sostelly, Alexandre, et al.
Publicado: (2019)

Critical appraisal of bevacizumab in the treatment of ovarian cancer
por: Yoshida, Hiroyuki, et al.
Publicado: (2015)

Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

Safety Analysis of Bevacizumab in Ovarian Cancer Patients
por: Wang, Yingwen, et al.
Publicado: (2023)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

The associations between serum vascular endothelial growth factor, tumor necrosis factor and interleukin 4 with the markers of blood–brain barrier breakdown in patients with paraneoplastic neurological syndromes
por: Michalak, Slawomir, et al.
Publicado: (2018)

Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
por: Desjardins, Annick, et al.
Publicado: (2019)

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
por: Kaparelou, Maria, et al.
Publicado: (2022)

Diffuse pulmonary lymphangiomatosis treated with bevacizumab
por: Onyeforo, Ernest, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_71s2fjmfudn7t04tep1iaoecg5